Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

JJ Miller, LN Gonzalez Castro, S McBrayer… - Neuro …, 2023 - academic.oup.com
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of …

MJ van den Bent, PJ French, D Brat, JC Tonn… - Neuro …, 2024 - academic.oup.com
Abstract The 2016 and 2021 World Health Organization 2021 Classification of central
nervous system tumors have resulted in a major improvement in the classification of …

Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma

A Bhatia, R Moreno, AS Reiner, S Nandakumar… - Clinical Cancer …, 2024 - AACR
Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain
tumors characterized by a slow-growing phase over several years followed by a rapid …

Impact of frontline ivosidenib on volumetric growth patterns in isocitrate dehydrogenase–mutant astrocytic and oligodendroglial tumors

DO Kamson, S Puri, Y Sang, MJ Shi, L Blair… - Clinical Cancer …, 2023 - AACR
Abstract Purpose: Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with
radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae …

IDH-mutant low-grade glioma: advances in molecular diagnosis, management, and future directions

A Dono, LY Ballester, D Primdahl, Y Esquenazi… - Current oncology …, 2021 - Springer
Purpose of Review IDH-mutant low-grade gliomas (LGG) have emerged as a distinct clinical
and molecular entity with unique treatment considerations. Here, we review updates in IDH …

Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors

BM Ellingson, ER Gerstner, AB Lassman… - Neuro …, 2022 - academic.oup.com
Imaging response assessment is a cornerstone of patient care and drug development in
oncology. Clinicians/clinical researchers rely on tumor imaging to estimate the impact of new …

Balancing risk and efficiency in drug development for rare and challenging tumors: a new paradigm for glioma

IK Mellinghoff, TF Cloughesy - Journal of Clinical Oncology, 2022 - ascopubs.org
The process of developing cancer therapies is well established and has enabled the
incorporation of many new drugs and classes of agents into the standard of care for common …

NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials …

AH Abayazeed, A Abbassy, M Müeller… - Neuro-oncology …, 2023 - academic.oup.com
Background Accurate and repeatable measurement of high-grade glioma (HGG) enhancing
(Enh.) and T2/FLAIR hyperintensity/edema (Ed.) is required for monitoring treatment …

Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery

G Cassinelli Petersen, K Bousabarah… - Neuro-Oncology …, 2022 - academic.oup.com
Background Treatment of brain metastases can be tailored to individual lesions with
treatments such as stereotactic radiosurgery. Accurate surveillance of lesions is a …

[HTML][HTML] AI-Driven image analysis in central nervous system tumors-traditional machine learning, deep learning and hybrid models

AV Krauze, Y Zhuge, R Zhao, E Tasci… - … of biotechnology and …, 2022 - ncbi.nlm.nih.gov
The interpretation of imaging in medicine in general and in oncology specifically remains
problematic due to several limitations which include the need to incorporate detailed clinical …